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Poulsen KA, Pedersen SF, Kolko M, Lambert IH. Induction of group VIA phospholipase A 2 activity during in vitro ischemia in C2C12 myotubes is associated with changes in the level of its splice variants. Am J Physiol Cell Physiol 293: C1605-C1615, 2007. First published August 31, 2007 ; doi: 10 .1152/ajpcell.00012.2007.-The involvement of group VI Ca 2ϩ -independent PLA2s (iPLA2-VI) in in vitro ischemia [oxygen and glucose deprivation (OGD)] in mouse C2C12 myotubes was investigated. OGD induced a time-dependent (0 -6 h) increase in bromoenol lactone (BEL)-sensitive iPLA 2 activity, which was suppressed by specific short interfering (si)RNA knockdown of iPLA2-VIA. OGD was associated with an increase in iPLA2-VIA protein levels, whereas mRNA levels were unchanged. The levels of iPLA2-VIB mRNA and protein were not increased by OGD. RT-PCR and Western blot analysis identified a mouse iPLA2-VIA homolog to catalytically inactive 50-kDa iPLA2-VIA-ankyrin variants previously identified in humans. Both the mRNA and protein levels of this ϳ50-kDa variant were reduced significantly within 1 h following OGD. In C2C12 myoblasts, iPLA2-VIA seemed to predominantly reside at the endoplasmatic reticulum, where it accumulated further during OGD. A time-dependent reduction in cell viability during the early OGD period (3 h) was partially prevented by iPLA2-VIA knockdown or pharmacological inhibition (10 M BEL), whereas iPLA2-VIA overexpression had no effect on cell viability. Taken together, these data demonstrate that OGD in C2C12 myotubes is associated with an increase in iPLA2-VIA activity that decreases cell viability. iPLA2-VIA activation may be modulated by changes in the levels of active and inactive iPLA2-VIA isoforms.
hypoxia; Ca 2ϩ -independent phospholipase A2-␤; Ca 2ϩ -independent phospholipase A2-␥ ISCHEMIA is a common and clinically important cause of injury in many tissues. In skeletal muscle, ischemia/hypoxia arises during circulatory and respiratory insufficiency and during surgery and trauma and is associated with a pronounced loss of function (14) .
Alterations in cell membrane structure and organization during ischemia are considered as important factors in determining the degree of irreversible damage (22) . Cell membrane composition and organization are partially regulated by a deacylation-reacylation cycle during which the sn-2 ester bonds of glycerophospholipids are hydrolyzed by PLA 2 followed by immediate reincorporation of new fatty acids by CoA-dependent acyltransferases maintaining a low cellular concentration of free fatty acids (FFA) and lysophospholipids (6) . This balance may become disturbed as a result of increased PLA 2 activity (20) , resulting in elevated levels of FFAs [e.g., arachidonic acid (AA)] and lysophopholipids [e.g., lysophosphatidylcholine (LPC)] (17, 41, 47, 50) . AA mediates a variety of pathophysiological responses either directly or indirectly when metabolized by cycloxygenases, lipoxygenases, or cytochrome P-450 (13) , whereas LPC is toxic in high concentrations due to its detergent-like properties, i.e., LPC increases membrane fluidity and permeability (20) . On the other hand, the activity of certain PLA 2 subtypes may have membrane repair functions and potentially provide protection during cellular stress (17, 41) . Thus, both protective and detrimental effects of PLA 2 activity in ischemia may be envisaged.
PLA 2 s are divided into four major families based on their nucleotide sequence: secretory low-molecular-weight PLA 2 s (sPLA 2 s), which require millimolar concentrations of Ca 2ϩ for catalytic activity; intracellular high-molecular-weight Ca 2ϩ -dependent PLA 2 s (cPLA 2 s), which require micromolar concentrations of Ca 2ϩ ; and Ca 2ϩ -independent PLA 2 s (iPLA 2 s) and platelet-activating factor acetylhydrolases (PAF-AHs) (28) .
Whereas the involvement of PLA 2 in the release of AA during ischemia/hypoxia has been established in some cells and tissues (41, 47, 50) , the level of PLA 2 activation and the regulation of the specific PLA 2 subtypes involved are incompletely understood. In a number of cell types, including cardiomyocytes (41), vascular smooth muscle cells (43) , and pancreatic ␤-cells (58), the majority of PLA 2 activity appears to be of the iPLA 2 type and sensitive to bromoenol lactone (BEL). Induction of iPLA 2 activity during ischemia has been demonstrated in ischemic rabbit hearts (21, 25) and proximal tubules (48) . Furthermore, in the myocardium, iPLA 2 activation is reported to be implicated in the induction of lethal malignant tachyarrhythmias due to increased phospholipid hydrolysis (36, 61) .
Two mammalian group VI iPLA 2 s, designated iPLA 2 -VIA and iPLA 2 -VIB, have been cloned (28) . iPLA 2 -VIA, also known as iPLA 2 -␤, has been implicated in diverse cellular processes including membrane remodeling (7), cell proliferation (39, 49) , cell volume regulation (see Refs. 29 and 31), insulin secretion (8), programmed cell death (see, e.g., Refs. 4, 46, and 52), and intracellular calcium mobilization (53) . iPLA 2 -VIA contains eight NH 2 -terminal ankyrin repeats plus a lipase consensus site, which appears to constitute a homotetramer in its functional form and possess PLA 2 , PLA 1 , and lysophospholipase as well as transacylase activity (1, 57) . The human iPLA 2 -VIA mRNA transcript is found in five different splice variants, of which two, termed iPLA 2 -VIA-1 and iPLA 2 -VIA-2, encode catalytically active proteins. iPLA 2 -VIA-2 is an extended version of iPLA 2 -VIA-1 that contains an additional 54-amino acid insert encoded by exon 9, which interrupts the last ankyrin repeat (32) . Two other splice variants, iPLA 2 -VIA-ankyrin-1 and iPLA 2 -VIA-ankyrin-2, are inactive forms of ϳ50 kDa that have maintained the ankyrin repeats but lack the COOH-terminal part containing the lipase motif (32) . The iPLA 2 -VIA-ankyrin variants have been proposed to regulate iPLA 2 -VIA activity in a dominant negative manner through interaction with the iPLA 2 -VIA functional unit (33, 39) . IPLA 2 -VIB, also designated iPLA 2 -␥, exhibits several splice variants (38) and different translational products originating from different in-frame start codons resulting in multiple expressed protein products (37) . iPLA 2 -VIB has been assigned roles in organelle membrane remodeling (44) and protection against oxidative stress (16) .
To date, little information is available on the expression and regulation of PLA 2 subtypes in skeletal muscle. In mouse skeletal muscle-derived myotubes (C2C12), we have previously demonstrated that simulated ischemia [oxygen and glucose deprivation (OGD)] increased the release of AA to the extracellular medium and that this was blocked by the iPLA 2 inhibitors BEL and arachidonyl trifluoromethyl ketone (31) . The present study addresses the role of iPLA 2 in AA accumulation during OGD in C2C12 myotubes. Here, we demonstrate that OGD-induced cell death is associated with an increase in iPLA 2 -VIA activity and involves changes in the levels of mRNA and protein for different iPLA 2 -VIA isoforms.
MATERIALS AND METHODS
Reagents and media. Unless otherwise indicated, reagents were of the highest available grade and obtained from Sigma-Aldrich (Brondby, Denmark). Alexa fluor 568-conjugated anti-mouse antibody was from Molecular Probes (Leyden, The Netherlands), and FITC-conjugated anti-rabbit antibody was from Jackson Immuno Research (Suffock, UK). Paraformaldehyde was prepared fresh regularly as a 20% stock solution in double-distilled (dd)H 2O, filtered, and kept at 4°C. The standard isotonic medium contained (in mM) 143 NaCl, 5 KCl, 1 Na 2HPO4, 1 CaCl2, 0.1 MgSO4, and 10 HEPES (pH 7.4). Tris-buffered saline (TBS) contained (in mM) 150 NaCl, 10 Tris ⅐ HCl, 1 MgCl 2, and 1 EGTA (pH 7.4).
Cell culture and ischemic simulation. The muscle cell culture used is a clone of the C2C12 myoblast cell line that was isolated and cultured as previously described (30) . Myoblasts were grown in 10 ml DMEM (catalog no. 32430, Invitrogen, Brondby, Denmark) supplemented with 10% FCS, 100 IU/ml penicillin, 100 g/ml streptomycin sulfate, 20 g/ml gentamicin, and 3 g/ml amphotericin B (Invitrogen). At confluence, the medium was changed to DMEM containing 2% FCS, and myoblasts were left to differentiate into multinucleated myotubes for 2-4 days. Cells were kept in an atmosphere of 95% air-5% CO 2 at 37°C. C2C12 myoblasts from passages 3 to 8 were used for experiments. The in vitro ischemia model was set up to combine the stresses of anoxia, glucose deprivation, and stagnant incubation medium (OGD). To create the ischemic environment for protein and mRNA extracts, cells were sealed in either 25-or 75-cm 2 culture flasks. Prior to the sealing step, media in the flasks were exchanged with a deoxygenated normal isotonic ringer and gassed with 100% N 2 for 2 min to eliminate oxygen from the remaining air space. Subsequently, the flasks were tightly sealed, preventing gas from entering. Cell lysates were isolated as described below but under a constant flow of N 2 . Preparation of cell lysates. C2C12 myotubes grown in 75-cm 2 culture flasks were washed in ice-cold PBS and lysed in ice-cold lysis buffer [for activity measurements: 50 mM HEPES, 1 mM EDTA, 1 mM Na-ortho-vanadate, and 1:100 (vol/vol) protease inhibitors containing AEBSF, pepstatin A, E-64, bestatin, leupeptin, and aprotinin (Sigma-Aldrich); and for Western blots: 20 mM HEPES, 150 mM NaCl, 1 mM EDTA, 10% glycerol, 1% Triton X-100, 1 mM Na-orthovanadate, and 1:100 (vol/vol) protease inhibitors]. Cells were scraped off and placed on ice. The resulting cell lysate was sonicated two times for 10 s on ice, the homogenate was centrifuged at 10,000 g at 4°C for 10 min, and the supernatant was transferred for protein determination. Cytosolic and mitochondrial fractions were separated using a mitochondria isolation kit from Pierce (catalog no. 89874, Rockford, IL) and the protocol supplied by the manufacturer. Membrane fractions was isolated as described by Haustetter et al. (24) . Lysates were stored at Ϫ80°C until use.
PLA 2 activity in cell lysates. C2C12 cell lysates were spun through 30-kDa cutoff filters (Millipore Microcon YM-30, 12 min, 14,000 g). Activity was measured using the PLA 2 substrate arachidonoyl thiophosphatidylcholine and the protocol recommended by the manufacturer (Cayman Chemical, Ann Harbor, MI). In brief, aliquots of 10 l of supernatants containing 60 -80 g protein were added to 96-well microtiter plates together with 5 l of assay buffer (80 mM HEPES, 150 mM NaCl, 10 mM CaCl 2, 4 mM Triton X-100, 30% glycerol, and 1 mg/ml BSA). Arachidonoyl thio-phosphatidylcholine was dissolved in 160 mM HEPES, 300 mM NaCl, 20 mM CaCl 2, 8 mM Triton X-100, 60% glycerol, and 2 mg/ml BSA and diluted 1:1 in ddH 2O. For measurements of Ca 2ϩ -independent activity, 10 mM CaCl2 was replaced with 5 mM EDTA. The reaction was initiated by the addition of 200 l of substrate to each well, allowed to run for 60 min, and stopped by the addition of 10 l of 25 mM 5,5Ј-dinitrobis-(2-dinitrobenzoic azid) (DTNB) plus 475 mM EGTA in 0.5 M Tris ⅐ HCl (pH 8.0). The absorbance was measured at 405 nm in a Fluostar Optima plate reader (BMG LabTechnologies, Offenburg, Germany). PLA2 activity was expressed in micromoles per milligram of protein per minute determined from the extinction coefficient of DNTB and the protein content in the supernatants using Lambert-Beer's law. BEL-sensitive PLA2 activity was estimated as the total activity minus activity in the presence of 10 M BEL.
Isolation of RNA, RT-PCR, and quantitative real-time PCR. Total RNA was isolated from C2C12 myotubes using the RNeasy Mini Kit (Qiagen, Ballerup, Denmark) according to the manufacturer's protocol. RNA quality was evaluated by gel electrophoresis. cDNA was prepared in a total volume of 40 l by hybridization of 500 ng random primers to 4 g RNA at 65°C for 5 min followed by extension at 42°C for 50 min in the presence of 200 units Superscript II reverse transcriptase (Invitrogen), 500 M dNTP, 10 M DTT, 50 mM Tris ⅐ HCl (pH 8.3), 75 mM KCl, and 3 mM MgCl2. Finally, the reverse transcriptase was inactivated at 70°C for 15 min. Conventional PCR was performed in a total volume of 20 l containing 1 l of RT reaction cDNA, 0.5 mM dNTPs, 0.5 M of each primer, 2 mM MgCl2, and 2 units Taq polymerase in PCR buffer [50 mM KCl and 10 mM Tris ⅐ HCl (pH 9.0)] and run for 35 cycles. Primers used for standard PCR were iPLA2-VIA, forward exon 8: 5Ј-TGGG-GAGACTCCTGCATTGA-3Ј, forward exon 9: 5Ј-AGCTGCAACT-CACCCCCTCT-3Ј, forward exon 12: 5Ј-GGAGTTCCTGAAGCGG-GAGT-3Ј, reverse exon 11: 5Ј-TCTGTCATCTTGGTGTGCTC-3Ј, and reverse exon 13: 5Ј-TGAGTCGGTGGCTTCAGGTT-3Ј; iPLA2-VIB, forward: 5Ј-GAATAACCCTTCGGCCTTGG-3Ј and reverse: 5Ј-AGAAGGCAACAGGCCATCAA-3Ј; iPLA2-␦, forward: 5Ј-TCACTGGGGAACCTCTCATC-3Ј and reverse: 5Ј-CTCCACAG-CTGTCCAGTCAA-3Ј; iPLA2-ε, forward: 5Ј ATGGCAAACTTG-TGGGAGAC-3Ј and reverse: 5Ј-GAGCATTCGATGGTCATCCT-3Ј; iPLA2-, forward: 5Ј-TCCGAGAGATGTGCAAACAG-3Ј and reverse: 5Ј-CTCCAGCGGCAGAGTATAGG-3Ј; cPLA2-IVA, forward: 5Ј-GTGGGCGAAAATGAACAAGC-3Ј and reverse: 5Ј-CGATTCG-GGGTCATCAAAAA-3Ј; cPLA2-IVB, forward: 5Ј-GGCACTGGC-CAACCTCTATG-3Ј and reverse: 5Ј-ATTGCTCCAGATGCCTTC-CA-3Ј; cPLA2-IVC, forward: 5Ј-ACCCTGCACTTGGGGCTTAT-3Ј and reverse: 5Ј-TCCTTGATGCTGGGGTCATT-3Ј; and PAF-AH(II), forward: 5Ј-GGTTCAGGGCGTCATACTCG-3Ј and reverse: 5Ј-AGCCGTAG-CTCCTCCAAAGG-3Ј. PCR products was confirmed by PCR cloning and sequencing. Real-time PCR was performed in triplicate using Stratagene MX4000 Real-Time PCR equipment and Taqman Univer-sal PCR Master Mix (ABI, Foster City, CA) in a total volume of 20 l containing 1 l of the RT reaction, 200 nM of probe and primers, and 10 l of 2ϫ Mastermix. Probe and primers for real-time PCR were designed to avoid amplification of genomic DNA using Primer Express (ABI, Foster City, CA) or MWG homepage software (MWG Biotech, Martinsried, Germany). Probe and primer sequences were iPLA 2-VIA, probe: 5Ј-CGGCATCCAGTACTTCAGACTGAACC-CC-3Ј, forward exon 16: 5Ј-GGGCCTGGTGCGAGATG-3Ј, and reverse exon 17: 5Ј-GCGTTGACCAGCACTGCAT-3Ј; iPLA2-VIA, exon 9 probe: 5Ј-CTCAGCCCCCAGCGATCAGCTTAAACAA-3Ј, forward exon 9: 5Ј-GACCACCACTTTCCAATCATC-3Ј, and reverse exon 10: 5Ј-TGGGCATGAGATCCTGAAG-3Ј; iPLA 2-VIA, exon 9A probe: 5Ј-TAGGCAGGCAGTCACTCAAACCAG-3Ј, forward exon 9A: 5Ј-CCCAGCGATCAGCTTAAAC-3Ј, reverse exon 10: 5Ј-TGGGCATGAGATCCTGAAG-3Ј; iPLA 2-VIB, probe: 5Ј-TCAAGATGGAGGTCTGCTTCTGAATAACCCT-3Ј, forward exon 7: 5Ј GCTCCAGGCTACTTTGCAGAGT-3Ј, and reverse exon 8: 5Ј-CCAGATGCATTTACATTCGTGAA-3Ј; and 18S rRNA, probe: 5Ј-TACCGCGGCTGCTGGCACC-3Ј, forward: 5Ј-TTTAATATAC-GCTATTGGAGCTGGAA-3Ј, and reverse: 5Ј-GGATCCATTG-GAGGGCAAGT-3Ј. Probes were labeled with FAM in the 5Ј-end and TAMRA in the 3Ј-end. The signal for mRNA expression was normalized to the reference gene level (18S rRNA), and the relative expression ratio was calculated using the following equation:
, where Etarget and Eref are the PCR amplification efficiencies for the target and reference gene (18S) and ⌬Ct target and ⌬Ct ref are the changes in threshold cycle (Ct) values for target and reference gene transcripts.
PCR cloning for sequencing. PCR products were cloned using TOPO TA cloning according to the manufacturer's instructions (Invitrogen). In brief, PCR products were extracted (Qiagen), ligated into the PCR-II TOPO vector, and transformed into Oneshot competent Escherichia coli. After a 30-min incubation on ice, cells were heat shocked for 30 s at 42°C, and 250 l SOC medium (2%) was added; 50 l of each transformation were plated on LB plates containing X-gal and ampicillin and left to incubate overnight. Positive colonies Oxygen and glucose deprivation (OGD) stimulates BEL-sensitive PLA2 activity in C2C12 myotubes. BEL-sensitive PLA2 activity in protein extracts from C2C12 myotubes was estimated throughout a 6-h OGD period. Cells were incubated under control (normoxic, 0 h) conditions or exposed to OGD for various time periods. Protein was extracted and assayed for PLA2 activity as described in MATERIALS AND METHODS in the absence and presence of 10 M BEL, and the difference was used to calculate BEL-sensitive activity. Protein samples taken under control conditions (0 h) and after 3 h of normoxia (ctrl) were used as controls. Values are mean Ϯ SE of 4 experiments. *Significantly different (P Ͻ 0.05) from 0 h normoxic control.
were picked and cultured in ampicillin containing LB medium for 18 h, and DNA was isolated (Perfectprep mini kit, Eppendorf, Horsholm, Denmark). Plasmids were analyzed by restriction analysis and sequenced (MWG Biotech).
Preparation of antibodies to iPLA 2-VIB. The generation of rabbit polyclonal antiserum was performed at the peptide synthesis and antibody production facilities at the Louisiana State University Health Sciences Center. A peptide corresponding to an epitope in the COOHterminal part of mouse and human iPLA 2-VIB (SHYLGGCQYK) was synthesized and conjugated to keyhole limpet hemocyanin carrier protein. Rabbits were immunized on day 0 and boosted again on days 14 and 21 with the conjugated peptide. Immunized serum was tested by ELISA before bleeding of the rabbits, the serum was prepared, and 0.1% sodium azide was added as a preservative. The antiserum was affinity purified with the use of the nonconjugated synthetic peptide and a Pierce AminoLink Plus Immobilization Kit, and the affinity purified antibody was desalted and concentrated using Millipore centricon YM50 columns according to the manufacturer's instructions.
Western blot analysis. For Western blot analysis, equivalent amounts of C2C12 protein (20 -30 g ) were separated by SDS-PAGE on precast NuPAGE 10% bis-Tris gels (Invitrogen). Proteins were transferred to nitrocellulose membranes, blocked in 5% nonfat dry milk in TBS for 1 h, and then incubated with primary antibody overnight {cPLA 2-IVA, 1:500 (sc-454, Santa Cruz Biotechnology, Santa Cruz, CA); iPLA2-VIA, 1:500 (sc-25504, Santa Cruz Biotech- Short interfering RNA knockdown of iPLA 2-VIA. The sequence (5Ј-AACAGCACAGAGAAUGAGGAG-3Ј) for the short interfering (si)RNA used was originally published by Su et al. (54) . Doublestranded RNA was subsequently synthesized by MGW Biotech. C2C12 myotubes were transfected with 20 nM siRNA complexed to GeneEraser transfection reagent according to the manufacturer's instructions (Stratagene, La Jolla, CA) and allowed to differentiate in 2% growth medium containing no antibiotics for another 48 h. The GeneEraser/siRNA-containing medium was removed prior to the launch of the experiments. Protein knockdown was evaluated by Western blot analysis and/or RT-PCR, and a scrambled siRNA (Santa Cruz Biotechnology) was used the negative control.
Transfection with iPLA 2-VIA vectors. C2C12 myoblasts or myotubes were transfected with control vector (pcDNA3), iPLA2-VIA-1 vector, or iPLA2-VIA-2 vector [a kind gift from Dr. Jackowski (15) Immunocytochemistry. C2C12 myoblasts were seeded at a density of 4,000 cells/well in eight-chamber polystyrene vessel glass slides (Becton Dickinson, Brondby, Denmark) and grown until 50 -60% confluence. Following stimulation, cells were fixed directly in the chambers with 2% paraformaldehyde, washed in PBS, and permeabilized for 15 min in 0.1% Triton X-100 in PBS. Permeabilized cells were washed, blocked in 2.5% BSA for 30 min, and labeled with rabbit iPLA 2-VIA (1:100, Cayman Chemical), mouse cytochrome c clone 6H2.B4 (1.250, BD Pharmingen, Erembodegem, Belgium), and 4 . Quantification of OGD-induced changes in mRNA levels for iPLA2-VIA and iPLA2-VIB. Total RNA was isolated from C2C12 myotubes exposed to OGD for 0 -6 h. RNA was reverse transcribed and cDNA was real-time PCR amplified using the Taqman Real-time PCR probe system. Primers and probes are described in MATERIALS AND METHODS. mRNA levels were normalized to the 18S rRNA housekeeping gene and shown relative to the normoxic control sample (0 h). Values are means Ϯ SE of 6 experiments. *Significantly different (P Ͻ 0.05) from the 0 h normoxic control. mouse protein disulphide-isomerase (PDI; 1:250, Affinity Bioreagents, Golden, CO) in PBS with 1% BSA overnight. Cells were washed three times in PBS with 1% BSA and incubated with FITCconjugated anti-rabbit and Alexa fluor 568-conjugated anti-mouse secondary antibodies (1:400) for 2 h. After three washes in PBS, the chamber vessel was removed, and slides were mounted [90% glycerol, 10% of 10ϫ PBS, and 2% (wt/vol) N-propylgalleate]. For OGD experiments, cells were incubated for 3-6 h in deoxygenated experimental solution in a controlled atmosphere incubator at 37°C with 0.1% CO 2 and 0.5% O2 (Jouan IG 750, Winchester, VA). Following OGD, cells were fixed with 2% paraformaldehyde under hypoxic conditions and treated as described above. Cells were visualized using the ϫ40/1.25 numerical aperture plan apochromat objective of a Leica DM IRB/E microscope with a Leica TSC NT confocal laser scanning unit (Leica Lasertechnik, Heidelberg, Germany). For all experiments, settings were carefully adjusted to avoid bleed through between the FITC and TRIC channels. No or negligible labeling was seen in the absence of primary antibodies (not shown). The optical slice thickness was 1 m. Images are frame averaged and shown in RGB pseudocolor.
Cell viability assay. Cell viability was determined using the MTT assay. C2C12 myoblasts were seeded in 96-well plates at a density of 2,000 cells/well, grown to confluence, and allowed to differentiate for 2-4 days. Transfections were performed in the last part of the differentiation period as described above (24 h for expression or 48 h for siRNA). Cells transfected with siRNA control (Santa Cruz Biotechnology) or control vector (pcDNA3, Invitrogen) were included and used to correct absorbance values in each experiment. Each condition was performed in at least triplicate. At the start of the experiments, the medium was replaced with 100 l experimental solution and incubated under normoxic or OGD conditions for 3-24 h. Two hours before the end of the incubation period 10 l of 2 mM MTT were added to the wells. For OGD, MTT was deoxygenated and added under hypoxic conditions. Experiments were timed such that equal cell growth/diffentiation times were ensured. Following incubation, cells were lysed in 100 l of 10 mM HCl containing 10% SDS and incubated for 18 h. Absorbance was read at 570 nm in a Fluostar Optima plate reader (BMG LabTechnologies), and cell death was expressed as the reduction in cell viability relative to normoxic controls. Fig. 5 . Changes in iPLA2-VIA, iPLA2-VIB, and cPLA2-IVA protein mass during OGD. Protein was isolated from C2C12 myotubes exposed to OGD for 0 -6 h and subjected to Western blot analysis. A: Western blots and quantification of the changes in the levels of iPLA2-VIA and cPLA2-IVA. B, right: Western blot showing expression of iPLA2-VIB isoforms during OGD in C2C12 myotubes. Left, quantification of the 63-kDa iPLA2-VIB isoform. All iPLA2-VIB isoforms were similar with respect to variations in intensity. Antibodies used were iPLA2-VIA (CAY-160507, 1:500), cPLA2-IVA (sc-454, 1:500), and iPLA2-VIB. Values are means Ϯ SE of 4 experiments for iPLA2-VIA and cPLA2-IVA and 3 experiments for iPLA2-VIB. *Significantly different (P Ͻ 0.05) from the 0 h normoxic control.
Statistics and data presentation. Data are presented as means Ϯ SE. Statistical significance was estimated by paired Student's t-test and/or one-way ANOVA, with 0.05 as the level of significance.
RESULTS
iPLA 2 activity in C2C12 myotubes was examined by assessing the BEL and Ca 2ϩ sensitivity of total PLA 2 activity toward a synthetic AA-containing substrate. As shown in Fig. 1A , total PLA 2 activity under control conditions was reduced by 40% following 20 min of preincubation with 10 M BEL. The omission of Ca 2ϩ from the activity buffer did not affect PLA 2 activity significantly, nor did it change the magnitude of BEL inhibition (Fig. 1A) . This indicates that 1) cPLA 2 activity constitutes a negligible fraction of the total PLA 2 activity and 2) ϳ60% of iPLA 2 activity implicates iPLA 2 s other that iPLA 2 -VIs. These may include BEL-insensitive iPLA 2 -IVC or iPLA 2 -VIIB [PAF-AH (II)], which was found to be expressed in C2C12 myotubes (Fig. 1B) . mRNAs for BELsensitive iPLA 2 -VIA, iPLA 2 -VIB, iPLA 2 -VIC (neuropathy target esterase), and iPLA 2 -VIE (TTS-2.2) were also expressed in C2C12 myotubes (Fig. 1B) . Subsequently, the BEL sensitivity of the total activity was used as a measure of iPLA 2 -VI activity. The BEL-sensitive fraction of PLA 2 activity was estimated at ϳ15 nmol⅐mg protein Ϫ1 ⅐min Ϫ1 under control conditions (normoxic) and gradually increased with time during OGD to a peak at ϳ35 nmol⅐mg protein Ϫ1 ⅐min Ϫ1 after 2-3 h (Fig. 2) . To investigate the specific involvement of iPLA 2 -VIA in OGD-induced PLA 2 activity, siRNA was employed. As shown in Fig. 3A , iPLA 2 -VIA expression was significantly reduced by iPLA 2 -VIA siRNA knockdown. Under normoxic conditions, iPLA 2 -VIA siRNA knockdown had only a minor effect on BEL-sensitive PLA 2 activity (Fig. 3B) . In contrast, OGD-induced BEL-sensitive PLA 2 activity was completely abolished by iPLA 2 -VIA siRNA knockdown, whereas it was unaffected in untreated or control siRNAtreated cells (Fig. 3B) . Thus, OGD-induced BEL-sensitive PLA 2 activity appears to be primarily mediated by iPLA 2 -VIA. During OGD, the mRNA level of iPLA 2 -VIA did not change significantly, whereas that of iPLA 2 -VIB declined following 2 h of OGD (Fig. 4) . At the protein level, iPLA 2 -VIA abundance increased moderately within the initial 1-3 h of OGD and remained elevated for the 6 h investigated (Fig. 5A) . In contrast, no changes in protein expression for cPLA 2 -IVA (Fig.  5A ) or in 63-, 77-, and 88-kDa iPLA 2 -VIB proteins (Fig. 5B) were detected. iPLA 2 -VIA catalytic activities are thought to be regulated through protein-protein interactions between active and inactive iPLA 2 -VIA isoforms, which are the product of alternative Fig. 6 . Identification of a mouse iPLA2-VIA-ankyrin splice variant. A: amplification of C2C12 cDNA using specific primers. Lane 1, amplification of C2C12 cDNA using primers forward exon 8 and reverse exon 11 (see MATERIALS AND METHODS). Gel fragments 3 and 4 in the gel were sequenced (sequence not shown) and shown to represent iPLA2-VIA-1 and iPLA2-VIA-2, respectively. Lane 2, amplification using primers forward exon 9 and reverse exon 11 (see MATERIALS AND METHODS). Both fragments 1 and 2 contain part of exon 9 (underlined) with fragment 2 containing the extra 29-bp insert between exon 9 and exon 10 (bold; designated here as exon 9A). B: sequence alignment of the two sequences obtained from fragments 1 and 2. C: DNA sequence alignment of mouse and human exon 9A and the mouse genomic sequence located at chromosome 15. Putative splice acceptor and donor sites are marked in bold.
mRNA splicing. The inactive variants, known as iPLA 2 -VIAankyrins (32, 33) , were initially identified from human sources, and their presence in mice has not yet been confirmed. Using primers designed to anneal on both sides of mouse exon 9 and 10 splice sites (forward exon 8 and reverse exon 11), two fragments were identified from C2C12 cDNA (Fig. 6A, lane 1) . DNA sequencing confirmed these to represent iPLA 2 -VIA-1 and VIA-2 transcripts (i.e., without and with 165-bp exon 9, respectively). Exchanging the forward primer with one that annealed inside exon 9 (forward exon 9) resulted in amplification of the two fragments (Fig. 6A, lane 2) . Both of these cDNAs contained the expected sequence of exon 9 with the longer form containing an extra insert of 29 bp inserted between the exon 9 and 10 splice sites (Fig. 6B) . The presence of this insert resulted in a frame shift inducing a stop codon inside exon 10. This transcript encodes a putative truncated iPLA 2 -VIA protein of ϳ53 kDa that lacks its COOH-terminal lipase consensus site.
The possible involvement of the iPLA 2 -VIA-ankyrin variant in regulating iPLA 2 -VIA activity was evaluated by tracking the expression of exon 9A-containing iPLA 2 -VIA mRNA transcripts through 6 h of OGD using quantitative real-time PCR. As the transcripts containing exon 9A also contain exon 9, a separate amplification of exon 9 was required to distinguish changes in exon 9A from changes in exon 9-containing mRNA. Using the exon-specific primers, the basal levels of exon 9-and exon 9A-containing iPLA 2 -VIA transcripts were estimated to be ϳ8-and 16-fold lower compared with the total iPLA 2 -VIA transcript level (data not shown, n ϭ 4). In contrast to the unchanged total iPLA 2 -VIA mRNA level throughout OGD (Fig. 4) , the level of exon 9A-containing transcript was significantly reduced within 30 min, whereas the level of exon 9-containing transcript was significantly reduced at 4 h of OGD (Fig. 7A ). An iPLA 2 -VIA antibody that has been shown to react with human iPLA 2 -VIA-ankyrin (39) recognized a protein of the expected 50 kDa in C2C12 protein lysates (Fig. 7B) . The level of the iPLA 2 -VIA-ankyrin protein was markedly reduced within the first hour of OGD (Fig. 7B) , indicating that the drop in iPLA 2 -VIA exon 9A mRNA is paralleled by a reduction in iPLA 2 -VIA-ankyrin protein levels. In resting C2C12 myoblasts, iPLA 2 -VIA seemed to localize throughout the cell but predominantly in the perinuclear region (Fig. 8A) . Following 3 and 6 h of OGD, iPLA 2 -VIA staining seemed to concentrate in a granular manner in the perinuclear region (Fig.  8A) . Substantial colocalization between iPLA 2 -VIA and the endoplasmic reticulum (ER) luminal protein PDI was observed both under control conditions and after 3 and 6 h of OGD. In contrast, colocalization between iPLA 2 -VIA and the mitochondrial marker cytochrome c was not detected under any condition (Fig. 8A) . Subcellular fractionation and Western blot analysis using VDAC as a mitochondrial marker showed that iPLA 2 -VIA was predominantly found in cytosolic and membrane fractions and verified that no, or very low levels of, iPLA 2 -VIA was present in isolated mitochondria (Fig. 8B) . No substantial changes in the subcellular distribution of iPLA 2 -VIA could be detected following 3 h of OGD (Fig. 8B) . While addressing this issue and its possible relevance to OGDinduced cell death is beyond the scope of the study, it may be noted that mitochondrial integrity appeared to be unperturbed in the time period studied, in contrast to our findings in cultured cardiomyocytes (2).
Finally, we evaluated the involvement of iPLA 2 -VIA in OGD-induced cell death in C2C12 myotubes. As shown in Fig.  9 , exposure to OGD was associated with a time-dependent loss of cell viability. Reduction of iPLA 2 -VIA protein level by siRNA-mediated knockdown or pharmacological inhibition of iPLA 2 using BEL (10 M) significantly attenuated cell death at 3 h of OGD but not after 6 h of OGD. In contrast, after 24 h of OGD, cell death was augmented by both BEL and iPLA 2 - Fig. 7 . Regulation of iPLA2-VIA-ankyrin mRNA and protein during OGD in C2C12 myotubes. A: quantitative real-time PCR showing the expression of exon 9-and exon 9A-containing mRNA transcripts normalized to 18S rRNA levels (relative expression). Data represent means Ϯ SE of 4 experiments. *Significantly different (P Ͻ 0.05) from the 0 h normoxic control. B: equal amounts of cell lysate from C2C12 myotubes were subjected to Western blot analysis using the iPLA2-VIA antibody (sc-25504), which recognizes the iPLA2-VIA-ankyrin variant. One of three representative blots is shown. iPLA2-VIA-ankyrin variant migrated very close to the 50-kDa marker. C: ratio of mRNA and protein of full-length iPLA2-VIA versus iPLA2-VIA-ankyrin following 0, 1, 2, 4, and 6 h of OGD stimulation. Data for the mRNA ratio were calculated as relative mRNA levels of total iPLA2-VIA mRNA (Fig. 5 ) over relative iPLA2-VIA exon 9A mRNA levels (A). The protein ratio was calculated from relative levels of full-length 85-kDa iPLA2-VIA protein (Fig.  6 ) and 50-kDa iPLA2-VIA-ankyrin from 3 blots (B).
VIA knockdown (Fig. 9A) . Conversely, overexpression of recombinant mouse iPLA 2 -VIA-1 or iPLA 2 -VIA-2 had no significant effect on ODG-induced cell death (Fig. 9B) .
DISCUSSION
Skeletal muscle ischemia/hypoxia is a clinical important phenomenon (14) . Although studies from other cell types have pointed to an important role for iPLA 2 in ischemic/hypoxicinduced cell damage (36, 48, 52, 61, 62) , this is, to our knowledge, the first study addressing the role of iPLA 2 s in skeletal muscle ischemia. The PLA 2 activity in C2C12 myotubes toward an AA-containing substrate was found to be mainly Ca 2ϩ independent and inhibited ϳ40% by BEL, implicating iPLA 2 -IVs in this activity. As chelation of Ca 2ϩ alone does not separate various iPLA 2 activities, we used BEL and/or siRNA to isolate iPLA 2 -VI activity. The finding that iPLA 2 -VIA siRNA knockdown had a relative limited effect on BELsensitive PLA 2 activity under normoxic conditions suggests that other BEL-sensitive PLA 2 s are active under basal conditions, e.g., iPLA 2 -VIB. mRNA for iPLA 2 -␦ and iPLA 2 -was also expressed in C2C12 myotubes; however, the activity of these PLA 2 s toward AA-containing phospholipids has been suggested to be low (26, 59) . Conversely, the BEL-sensitive PLA 2 activity induced by OGD was completely prevented in iPLA 2 -VIA siRNA-treated C2C12 myotubes, strongly indicating that iPLA 2 -VIA is activated by OGD. In congruence with this, hypoxia-induced iPLA 2 activity also appears to be mediated by iPLA 2 -VIA in PC12 cells (52) .
The changes in OGD-induced activity correlated with the time scale for changes in iPLA 2 -VIA protein, indicating that increased activity, at least in part, reflects increased protein mass. The absence of a change in iPLA 2 -VIA mRNA compared with that of the protein suggests that long-term regulation of iPLA 2 -VIA activity in response to OGD predominantly occurs at the translational and/or posttranslational levels. The OGD-induced induction appears to be specific for iPLA 2 -VIA, since neither the mRNA nor protein level of iPLA 2 -VIB was affected by OGD.
The activity of the iPLA 2 -VIA enzyme complex may be modulated by changes in the ratio of active versus inactive iPLA 2 -VIA isoforms. The iPLA 2 -VIA-ankyrin splice variants are characterized by additional short sequences, encoded by exon 9A and 10A, spliced into the mRNA transcript after exon 9 and 10, resulting in frame shifts, the introduction of premature stop codons, and truncated protein products. Larsson and coworkers (33) initially demonstrated that coexpression of full-length and truncated iPLA 2 -VIA-ankyrin variants suppressed iPLA 2 activity, and later findings in CHO cells transfected with hamster iPLA 2 -VIA and human iPLA 2 -VIAankyrin-1 indicated that it was due to a direct interaction Fig. 8 . Subcellular localization of iPLA2-VIA. A: C2C12 myoblasts were seeded in 8-chamber polystyrene vessel glass slides, exposed to OGD for the times indicated, fixed with paraformaldehyde, permeabilized, blocked for unspecific protein binding, and labeled with primary antibody [iPLA2-VIA, cytochrome c (Cyt C), and protein disulphide-isomerase (PDI)] in PBS with 1% BSA overnight. Following incubation, cells were washed, incubated with FITC-conjugated anti-rabbit and Alexa568 anti-mouse secondary antibodies (1:400) for 2 h, and mounted (for details, see MATERIALS AND METHODS). For ODG, cells were incubated for 3 and 6 h in deoxygenated experimental solution in a controlled atmosphere incubator at 37°C with 0.1% CO2-0.5% O2 followed by paraformaldehyde fixation under hypoxic conditions and subsequent treatments as above. Cells were visualized using the ϫ40/1.25 numerical aperture plan apochromat objective of a Leica DM IRB/E microscope with a Leica TSC NT confocal laser scanning unit. Settings were carefully adjusted to avoid bleed through between the FITC and TRIC channels. No or negligible labeling was seen in the absence of primary antibodies (not shown). The optical slice thickness was 1 m, and images were frame averaged and are shown in RGB pseudocolor. The yellow signal in the merge images indicates the colocalization of iPLA2-VIA and the endoplasmic reticulum (ER) marker PDI. B: Western blots showing subcellular localization of iPLA2-VIA under control conditions and following 3 h of OGD. C, cytosol; Mi, mitochondria; Me, crude membrane. Voltage-dependent anion channel (VDAC) was used as a marker for mitochondria. Membrane fractions were enriched in the ER resident proteins TMX3 and ERp57 (data not shown). Different antibodies had to be used for the Western blots as the Cyt C and PDI antibodies used for the confocal imaging were not recommended for Western blotting by the manufacturers.
between iPLA 2 -VIA variants (39) . The variant of the mouse iPLA 2 -VIA transcript identified in the present study appears to be a homolog to human iPLA 2 -VIA-ankyrins. The 29-bp insert is found in the mouse genome at chromosome 15 in the intron spaced between iPLA 2 -VIA exon 9 and 10. Although 24 bp shorter, it has ϳ90% homology to the first part of human exon 9A (Fig. 6C) . Notably, the mRNA level of this iPLA 2 -VIAankyrin transcript variant was reduced within 30 min of OGD, whereas the total iPLA 2 -VIA mRNA level was not significantly altered. iPLA 2 -VIA-ankyrin protein mass was likewise found to be reduced within 1 h during OGD. Interestingly, although the basal level of iPLA 2 -VIA-ankyrin mRNA was fairly low, the protein level was high compared with full-length active forms. Thus, if the scenario of an inhibitory interaction between the enzymatically active iPLA 2 -VIA and iPLA 2 -VIAankyrin is correct, a significant increase in the ratio of active to inactive protein variants during OGD would be required to lift this inhibition. Consistent with this notion, the mRNA ratio increased ϳ2.5-fold and the protein ratio increased ϳ8-fold during OGD (Fig. 7C) . Hence, the increase in BEL-sensitive activity during OGD may, at least in part, be controlled by a combination of upregulation of active iPLA 2 -VIA isoforms and downregulation of inactive isoforms. Whether these changes involve increased synthesis or reduced degradation or a combination of both was not investigated.
Localization of iPLA 2 -VIA in specific cellular compartments (9, 12, 19, 45, 51, 52, 61) and subcellular relocation of the lipase upon activation have previously been demonstrated (45, 60) . However, it is unclear whether iPLA 2 -VIA relocates in response to ischemic stress. OGD in C2C12 was [in agreement with findings in human colon cancer (35) , kidney cells (18) and ␤-cells (9)] associated with increased iPLA 2 -VIA intensity in the perinuclear region in organelles, which appeared to be the ER (Fig. 8A ). This intensity increase does apparently not reflect iPLA 2 -VIA translocation from the cytosol to the ER as subcellular fractionation did not shown major changes in the subcellular distribution pattern following 3 h of OGD (Fig. 8B) . iPLA 2 -VIA was, in contrast to findings in other cell lines (11, 12, 23, 35, 51, 61) , absent from, or very weakly expressed in, mitochondria. In PC12 cells, iPLA 2 -VIA has been shown to translocate into the nucleus during hypoxia (52); however, we did not find evidence for nuclear translocation in C2C12 myoblasts. Thus, these findings are most consistent with the interpretation that iPLA 2 -VIA is primarily targeted to the ER in C2C12 cells, where it is concentrated during OGD.
A number of studies have reported that iPLA 2 has protective functions in certain cell types, primarily under oxidative stress conditions (16, 18, 37, 42, 55, 56) . Conversely, PLA 2 may also mediate cell damage following various death-inducing stimuli in other cell systems (3, 17, 61) , including during severe oxidative stress (5, 10, 40) . In C2C12 myotubes, siRNA knockdown or pharmacological inhibition of iPLA 2 -VIA was found to moderately counteract OGD-induced cell death in the early OGD phase, whereas in the late phase (24 h), cell death was slightly but significantly increased. In contrast to the effect of inhibition/knockdown, overexpression of iPLA 2 -VIA did not affect cell viability in C2C12 cells. Thus, although these data indicate that iPLA 2 -VIA activity may have both damaging and protective functions depending on the degree of exposure to OGD, the moderate effect of its inactivation on cell viability suggests that iPLA 2 -VIA is not an indispensable mediator of the cell death response under these conditions. It is possible that the role of iPLA 2 -VIA may vary with the specific death pathways activated, a question not addressed in the present study. The physiological function of iPLA 2 -VIA in the ER Fig. 9 . Involvement of iPLA2-VIA in OGD-induced cell death. C2C12 myotubes were cultured in 96-well plates and exposed to normoxia or OGD for 3, 6, and 24 h. A: effect of iPLA2-VIA siRNA knockdown and iPLA2 inhibition (10 M BEL) on cell viability. Cells were either pretreated with siRNA targeting iPLA2-VIA for 48 h (20 nM) or BEL was added to the incubation medium prior to the start of the experiments. A control siRNA (Ctrl) was included and used to correct iPLA2-VIA siRNA values. B: effect of iPLA2-VIA expression on cell viability. Expressions of iPLA2-VIA-1 or iPLA2-VIA-2 in C2C12 myotubes following 24 h of transfection were verified in Western blots. Mock, nontransfected cells; VIA-1, cells transfected with iPLA2-VIA-1; VIA-2, cells transfected with iPLA2-VIA-2. For cell viability measurements, C2C12 myotubes were transfected iPLA2-VIA-1 or iPLA2-VIA-2 24 h before the start of the experiments. The effect of transfection with the control vector (pcDNA3) on cell viability was used to correct the values of iPLA2-VIA-transfected cells. Cell viability was estimated using the MTT activity assay. Values are means Ϯ SE of 5 experiments in 2 separate series of experiments (A and B) and presented as the relative reduction in cell viability (cell death). *Significantly different from normoxia (0 h); #significantly different from 3 and 24 h of OGD. during OGD is unclear; however, studies on ER iPLA 2 s in oxidant-induced cell death have indicated that ER PLA 2 activity may protect against oxidative stress-induced lipid peroxidation (18, 27) . On the other hand, iPLA 2 -VIA has also been proposed to participate in ceramide generation during ER stress-induced apoptosis in INS-1 cells (34) . The damaging effects of iPLA 2 -VIA in the early OGD period might otherwise be mediated by release of FFAs that affect cell signaling or mitochondrial permeability/function (12), by direct disruption of phospholipid membranes (17) , or by altering nuclear membrane architecture (52) .
In conclusion, deprivation of C2C12 myotubes of oxygen and glycose (OGD) induced specific activation of iPLA 2 -VIA and reciprocal changes in the expression levels of active and inactive iPLA 2 -VIA splice variants. iPLA 2 -VIA accumulated in the perinuclear area, apparently the ER, during OGD. Although not essential for loss of cell viability during OGD, increased iPLA 2 -VIA activity contributes to the reduced cell viability in the early OGD phase. Together, these findings indicate that iPLA 2 -VIA activity is an important element of ischemic cell injury in skeletal muscle.
